Page 1147 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPter 81 Concepts and Challenges in Organ Transplantation 1113

6. Whitelegg A, Barber LD. The structural basis of T-cell allorecognition. 30. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for
+
+
+
Tissue Antigens 2004;63(2):101–8. anti-thymocyte globulin: induction of CD4 CD25 Foxp3 regulatory T
7. Lakkis FG, Arakelov A, Konieczny BT, et al. Immunologic “ignorance” of cells. J Am Soc Nephrol 2006;17(10):2844–53.
vascularized organ transplants in the absence of secondary lymphoid 31. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath
tissue. Nat Med 2000;6(6):686–8. 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.
8. Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility Lancet 1998;351(9117):1701–2.
complex allorecognition. Curr Opin Organ Transplant 2008;13(4):438–44. 32. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H)
9. Auchincloss H Jr, Sultan H. Antigen processing and presentation in induction therapy in cadaveric kidney transplantation—efficacy and
transplantation. Curr Opin Immunol 1996;8(5):681–7. safety at five years. Am J Transplant 2005;5(6):1347–53.
10. Smyth LA, Herrera OB, Golshayan D, et al. A novel pathway of antigen 33. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier
presentation by dendritic and endothelial cells: implications for to transplantation tolerance. Nat Med 2004;10(1):87–92.
allorecognition and infectious diseases. Transplantation 2006;82(1 34. Trzonkowski P, Zilvetti M, Friend P, et al. Recipient memory-like
Suppl.):S15–18. lymphocytes remain unresponsive to graft antigens after CAMPATH- 1H
11. Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft induction with reduced maintenance immunosuppression.
rejection and tolerance. Transplantation 2005;80(5):555–63. Transplantation 2006;82(10):1342–51.
12. Heidt S, Segundo DS, Chadha R, et al. The impact of Th17 cells on 35. Hanaway MJ, Woodle SE, Mulgaonkar S, et al. Alemtuzumab Induction in
transplant rejection and the induction of tolerance. Curr Opin Organ Renal Transplantation. NEJM 2011;364(20):1909–19.
Transplant 2010;15(4):456–61. 36. The 3C Study Collaborative Group, Haynes R, Harden P, et al.
13. Feng G, Chan T, Wood KJ, et al. Donor reactive regulatory T cells. Curr Alemtuzumab-based induction treatment versus basiliximab-based
Opin Organ Transplant 2009;14(4):432–8. induction treatment in kidney transplantation (the 3C Study): a
14. Gill RG. NK cells: elusive participants in transplantation immunity and randomised trial. Lancet 2014;384(9955):1684–90.
tolerance. Curr Opin Immunol 2010;22(5):649–54. 37. Shyu S, Dew MA, Pilewski JM, et al. Five-year outcomes with
15. Nath DS, Basha HI, Mohanakumar T. Antihuman leukocyte antigen alemtuzumab induction after lung transplantation. J Heart Lung
antibody-induced autoimmunity: role in chronic rejection. Curr Opin Transplant 2011;30(7):743–54.
Organ Transplant 2010;15(1):16–20. 38. Willicombe M, Brookes P, Santos-Nunez E, et al. Outcome of patients
16. Rosenberg AS. The T cell populations mediating rejection of MHC class I with preformed donor-specific antibodies following alemtuzumab
disparate skin grafts in mice. Transpl Immunol 1993;1(2):93–9. induction and tacrolimus monotherapy. Am J Transplant
17. Cramer DV, Wu GD, Chapman FA, et al. Lymphocytic subsets and 2011;11(3):470–7.
histopathologic changes associated with the development of heart 39. Knechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of
transplant arteriosclerosis. J Heart Lung Transplant 1992;11(3 Pt tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen
1):458–66. for kidney transplantation: clinical results and immune monitoring. Am J
18. Gebel HM, Bray RA. The evolution and clinical impact of human Transplant 2009;9(5):1087–98.
leukocyte antigen technology. Curr Opin Nephrol Hypertens 40. Bloom D, Chang Z, Pauly K, et al. BAFF is increased in renal transplant
2010;19(6):598–602. patients following treatment with alemtuzumab. Am J Transplant
19. Leffell MS, Zachary AA. Antiallograft antibodies: relevance, detection, and 2009;9(8):1835–45.
monitoring. Curr Opin Organ Transplant 2010;15(1):2–7. 41. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the
20. Sanchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and treatment of autoimmunity. Nat Rev Immunol 2007;7(8):622–32.
tolerance following transplantation of liver or other solid organs. 42. Ablamunits V, Bisikirska B, Herold KC. Acquisition of regulatory function
Gastroenterology 2011;140(1):51–64. by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.
21. de Fijter JW. Rejection and function and chronic allograft dysfunction. Eur J Immunol 2010;40(10):2891–901.
Kidney Int Suppl 2010;119:S38–41. 43. Golshayan D, Pascual M. Tolerance-inducing immunosuppressive
22. Veronese FV, Noronha IL, Manfro RC, et al. Prevalence and strategies in clinical transplantation: an overview. Drugs
immunohistochemical findings of subclinical kidney allograft rejection 2008;68(15):2113–30.
and its association with graft outcome. Clin Transplant 44. Knechtle SJ. Immunoregulation and tolerance. Transplant Proc 2010;42(9
2004;18(4):357–64. Suppl.):S13–15.
23. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal 45. Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls
immunosuppression after pretransplant lymphoid depletion with peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol
Thymoglobulin or Campath. J Am Coll Surg 2005;200(4):505–15, quiz 2003;171(7):3348–52.
A59–61. 46. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and
24. Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): interleukin 2 receptor blockade on regulatory T cells in renal
a review of its use in the prevention and treatment of acute renal allograft transplantation. Am J Transplant 2008;8(10):2086–96.
rejection. Drugs 2009;69(11):1483–512. 47. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of
25. Charpentier B, Rostaing L, Berthoux F, et al. A three-arm study belatacept-based immunosuppression regimens versus cyclosporine in
comparing immediate tacrolimus therapy with antithymocyte globulin renal transplant recipients (BENEFIT study). Am J Transplant
induction therapy followed by tacrolimus or cyclosporine A in adult renal 2010;10(3):535–46.
transplant recipients. Transplantation 2003;75(6):844–51. 48. Larsen CP, Grinyó J, Medina-Pestana J, et al. Belatacept-based regimens
26. Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduction versus a cyclosporine A-based regimen in kidney transplant recipients:
in renal transplant recipients with tacrolimus-based immunosuppression. 2-year results from the BENEFIT and BENEFIT-EXT studies.
Transplantation 2001;72(6):1050–5. Transplantation 2010;90(12):1528–35.
27. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review 49. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and
in organ transplantation. Transplantation 2006;81(10):1361–7. Long-Term Outcomes in Kidney Transplantation. NEJM
28. Trzonkowski P, Zilvetti M, Chapman S, et al. Homeostatic repopulation 2016;374(4):333–43.
by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant 50. Vincenti F, de Andrés A, Becker T, et al. Interleukin-2 receptor antagonist
recipients treated with reduced immunosuppression. Am J Transplant induction in modern immunosuppression regimens for renal transplant
2008;8(2):338–47. recipients. Transpl Int 2006;19(6):446–57.
29. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a 51. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor
memory-like phenotype are the dominant cell type following antibody- antagonists for renal transplant recipients: a meta-analysis of randomized
mediated T-cell depletion. Am J Transplant 2005;5(3):465–74. trials. Transplantation 2004;77(2):166–76.